Spruce Biosciences
Founded Year
2014Stage
IPO | IPOTotal Raised
$108MDate of IPO
10/9/2020Market Cap
0.09BStock Price
2.44About Spruce Biosciences
Spruce Biosciences (NASDAQ: SPRB) is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company's mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the "stress pathway").
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Spruce Biosciences Patents
Spruce Biosciences has filed 14 patents.
The 3 most popular patent topics include:
- Pregnanes
- Neuroendocrinology
- Peptide hormones
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/13/2022 | 7/25/2023 | G protein coupled receptors, Peptide hormones, Peptides, Neuroendocrinology, Neuropeptides | Grant |
Application Date | 4/13/2022 |
|---|---|
Grant Date | 7/25/2023 |
Title | |
Related Topics | G protein coupled receptors, Peptide hormones, Peptides, Neuroendocrinology, Neuropeptides |
Status | Grant |
Latest Spruce Biosciences News
Sep 12, 2023
solidcolours Neurocrine Biosciences ( NBIX ) said Tuesday its CRF1 antagonist crinecerfont for classic congenital adrenal hyperplasia (CAH) met the primary endpoint in a Phase 3 trial, rallying the shares of Spruce Biosciences (NASDAQ: SPRB ), a rival developer with a similar candidate in its pipeline. Citing topline data, Neurocrine ( NBIX ) said that crinecerfont reached the primary goal and key secondary endpoints in its CAHtalyst registrational trial. After the results, RBC Capital Markets argued that the CAHtalyst readout validated the potential of "CRF1 antagonism" in CAH. Spruce ( SPRB ) is advancing its CRF1 antagonist, tildacerfont, in CAHmelia-203. The Phase 2b placebo-controlled trial involving adults with classic CAH is expected to generate topline data in H2 2023. Last week, Leerink Partners upgraded SPRB to Outperform from Market Perform, expecting positive CAHmelia-203 data.
Spruce Biosciences Frequently Asked Questions (FAQ)
When was Spruce Biosciences founded?
Spruce Biosciences was founded in 2014.
Where is Spruce Biosciences's headquarters?
Spruce Biosciences's headquarters is located at 2001 Junipero Serra Blvd., San Francisco.
What is Spruce Biosciences's latest funding round?
Spruce Biosciences's latest funding round is IPO.
How much did Spruce Biosciences raise?
Spruce Biosciences raised a total of $108M.
Who are the investors of Spruce Biosciences?
Investors of Spruce Biosciences include RiverVest Venture Partners, Novo Ventures, Aisling Capital, Abingworth, Sands Capital and 6 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
